This site is intended for Healthcare professionals only.

ADA releases major updates to 2019 Standards of Medical Care in Diabetes

ADA releases major updates to 2019 Standards of Medical Care in Diabetes

The American Diabetes Association(ADA) has issued important updates to the 2019 Standards of Medical Care in Diabetes, earlier reported by Speciality Medical Dialogues on December 19, 2018. The updates are published online in Diabetes Care.

Updates to the Standards of Care are established and revised by the ADA’s Professional Practice Committee (PPC). The committee is a multidisciplinary team of 14 leading U.S. experts in the field of diabetes care and includes physicians, diabetes educators, registered dietitians and others whose experience includes adult and pediatric endocrinology, epidemiology, public health, lipid research, hypertension,  preconception  planning and pregnancy care.

The Standards of Care provide the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2 or gestational diabetes; strategies to improve the prevention or delay of type 2 diabetes; and therapeutic approaches that reduce complications and positively affect health outcomes. Beginning in 2018, the ADA updates and revises the online version of the Standards of Care throughout the year, with annotations for new evidence or regulatory changes that merit immediate incorporation. The online version of the Standards of Care will include any research updates or policy changes that are approved throughout 2019.

The March 27 Living Standards of Care updates are as follows:

  • Section 10 was updated based on the outcome of Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), which determined the addition of icosapent ethyl to statin therapy for patients with high triglyceride levels reduced cardiovascular events. The Standards of Care now include a recommendation that icosapent ethyl be considered for patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) or other cardiac risk factors on a statin with controlled LDL-C, but with elevated triglycerides (135-499) to reduce cardiovascular risk.
  • Sections 910, and 11 have been revised based on findings from The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) Trial, in which dapagliflozin treatment showed a reduction of hospitalization for heart failure and a reduction in progression of chronic kidney disease (CKD).
  • Based on a revision to the prescribing information for dapagliflozin, for patients with diabetes and CKD, the approved use per estimated glomerular filtration rate (eGFR) has been revised from ≥60 mL/min/1.73 m2 to ≥45 mL/min/1.73 m2 in Section 11 of the Standards of Care.

“New research can lead to improved patient outcomes and quality of life, and the American Diabetes Association is proud to continue to provide the most current evidence-based guidelines for people living with diabetes. These Living Standards of Care updates via the online annotations to our yearly Standards of Care enable us to translate and communicate significant research findings that will empower health professionals to provide optimal care for millions of Americans living with diabetes,” said the ADA’s Chief Scientific, Medical and Mission Officer William T. Cefalu, MD.

The complete, annotated Standards of Care, which includes updates made today, can be accessed online on Diabetes Care. The Abridged Standards of Medical Care in Diabetes have also been updated and can be accessed online on Clinical Diabetes.

Spread the love

Source: With inputs from Diabetes Care and Clinical Diabetes

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted